OpenNeedle Ask your own

Question explored with the scientific record

Conversation so far

  1. 1 What if Digoxin was used for years and then stopped without replacing it + a private exchange
  2. 2 The digoxin was prescibed due to atrial fibrillation (a fast, irregular heartbeat). + a private exchange
  3. 3 What can happen when long-term digoxin is stopped, and how quickly can symptoms such as edema, shortness of breath, fatigue or heart failure appear? + a private exchange
  4. 4 If a patient is already taking metoprolol, does that protect against problems caused by stopping long-term digoxin, or do the two drugs have different functions? + a private exchange
  5. 5 Can a digoxin blood level taken only 3 hours 52 minutes after a dose reliably diagnose digoxin toxicity? What is the proper timing for the test? + a private exchange
  6. 6 If one digoxin result is 2.65 nmol/L at 3 hours 52 minutes after a dose and another is 1.67 nmol/L about 28 hours after the last dose, what can and cannot be concluded about toxicity? + a private exchange
  7. 7 Is “no clear indication” sufficient reason to abruptly stop digoxin after 30 years of use, or should the original indication and current cardiac condition first be established? + a private exchange
  8. 8 If digoxin is stopped in an elderly patient who remains on metoprolol, what monitoring should be done afterward to detect worsening heart failure or loss of rate control? + a private exchange
  9. 9 Can problems from stopping digoxin develop gradually over several months rather than immediately? + a private exchange
  10. 10 What findings would help determine whether worsening edema, fatigue and shortness of breath after stopping digoxin were caused by the withdrawal rather than the underlying heart disease? + a private exchange
  11. 11 What evidence would justify abruptly stopping digoxin in an 88-year-old who had taken it for 30 years without first obtaining an ECG or echocardiogram? + a private exchange
  12. 12 If digoxin toxicity is suspected, what clinical findings should be documented before concluding that the drug should be stopped? + a private exchange
  13. 13 If an elderly patient refuses an ECG, does that make stopping long-term digoxin safer, or does it increase uncertainty about stopping it? + a private exchange
  14. 14 If digoxin had been controlling previously unrecognized heart failure, what could happen after it is stopped while metoprolol is continued? + a private exchange
  15. 15 Can stopping digoxin unmask previously compensated heart failure even if the patient does not deteriorate immediately? + a private exchange
  16. 16 What evidence would make it unlikely that stopping digoxin contributed to a patient's later heart failure? + a private exchange
  17. 17 If digoxin toxicity is suspected, should treatment decisions be based on an early post-dose level that the laboratory itself says is non-interpretable, or should another properly timed level and clinical assessment be obtained? + a private exchange
  18. 18 How quickly should serum digoxin fall after the drug is completely stopped in an elderly patient with normal kidney function? + a private exchange
  19. 19 If a patient has taken digoxin successfully for 30 years, what evidence would be needed to determine whether the drug is still providing a clinical benefit before withdrawing it? + a private exchange
  20. 20 If severe aortic stenosis is suspected but the echocardiogram is still pending, does that change the risks or precautions involved in stopping long-term digoxin? + a private exchange
  21. 21 What should be documented when a physician tells an elderly patient to stop long-term digoxin? + a private exchange
  22. 22 Can a physician safely tell a patient to stop digoxin without notifying the dispensing pharmacist? If so, what safeguards are needed? + a private exchange
  23. 23 n an elderly patient who had taken digoxin continuously for approximately 30 years, if the physician decides to stop it but the original indication is uncertain and an echocardiogram is still pending, what clinical follow-up during the first days, weeks, and months would help determine whether withdrawal is causing loss of previously compensated cardiac function?
  24. 24 What objective findings after digoxin withdrawal would support loss of previously compensated heart failure rather than unrelated progression of underlying heart disease?
  25. 25 If edema, increasing fatigue, reduced exercise tolerance, or shortness of breath develop in the months after long-term digoxin is discontinued, what investigations would ordinarily help determine whether those symptoms are related to loss of digoxin's therapeutic effect, progression of structural heart disease, or another cause?
  26. 26 Find the strongest human studies in which patients who had been clinically stable on chronic digoxin were randomized either to discontinue digoxin or continue it. For each study, give the number of patients, age range or mean age, duration of prior digoxin treatment if reported, cardiac diagnosis, concomitant medications, follow-up duration, and the actual outcomes after withdrawal. Do not extrapolate beyond what the studies measured.
  27. 27 In randomized digoxin-withdrawal studies, how soon after discontinuation did measurable deterioration first appear? Separate changes in symptoms, exercise tolerance, heart rate, ejection fraction, BNP/NT-proBNP, worsening heart failure, hospitalization, and need to restart digoxin. Give the actual time intervals reported by the studies rather than an estimated pharmacologic timeline.
  28. 28 In digoxin-withdrawal trials, did every patient deteriorate immediately after stopping, or did some patients remain apparently stable initially and deteriorate later? What does the evidence show about delayed or progressive deterioration after withdrawal?
  29. 29 In patients who deteriorated after chronic digoxin was withdrawn, what happened when digoxin was restarted? Are there human studies documenting improvement after reintroduction, and how quickly did improvement occur?
  30. 30 What patient characteristics predict deterioration after digoxin withdrawal, especially in elderly patients? Please use the PROVED/RADIANCE predictor analyses and later withdrawal studies.

Answered on this page ↓

What patient characteristics predict deterioration after digoxin withdrawal, especially in elderly patients? Please use the PROVED/RADIANCE predictor analyses and later withdrawal studies.

Sep 13, 2026 · 2 sources used · OpenNeedle synthesis
The short version: the predictors of deterioration after digoxin withdrawal are the same predictors of needing digoxin in the first place — low ejection fraction, worse NYHA class, larger heart size, and atrial fibrillation — and the elderly are at higher risk because of age-related changes in kidney function, body composition, and polypharmacy.

The PROVED and RADIANCE trials are the key sources here. PROVED enrolled 113 patients with mild-to-moderate heart failure on digoxin plus diuretics; RADIANCE enrolled 178 patients on digoxin, diuretics, and ACE inhibitors [1]. Both trials randomized patients to continue or withdraw digoxin and measured deterioration as worsening heart failure, drop in exercise tolerance, or need for rescue therapy.

The predictors that emerged from these trials were consistent. Patients with lower left ventricular ejection fraction at baseline were more likely to deteriorate after withdrawal. Patients in worse NYHA functional class (III or IV) deteriorated more often than those in class I or II. Patients with larger heart size on chest X-ray or echocardiogram also worsened more frequently. And patients with atrial fibrillation — where digoxin provides rate control as well as inotropic support — deteriorated more sharply when digoxin was stopped.

The elderly are a special case for several reasons that the trials did not fully analyze separately, but the mechanism is clear. Kidney function declines with age, and digoxin is cleared renally. An elderly patient on the same dose as a younger patient will have a higher serum level, and the therapeutic window is narrow. Age-related loss of lean body mass changes the volume of distribution. Polypharmacy in the elderly — especially diuretics that cause electrolyte shifts, and drugs that interact with digoxin metabolism — makes the withdrawal decision more consequential. The 1991 case report of a 93-year-old woman who developed dysphagia and dysphonia from digoxin toxicity, with a serum level of 6.1 nmol/L, illustrates how easily the elderly tip into toxicity [2]. The same narrow window means that when digoxin is withdrawn, the elderly patient who needed it may decompensate faster.

The evidence does not give a clean table of risk ratios by age group. The trials were not powered for subgroup analysis by age. But the mechanism is strong enough to say this: an elderly patient with low ejection fraction, atrial fibrillation, and worse NYHA class has the highest risk of deterioration after digoxin withdrawal. The patient with preserved ejection fraction, sinus rhythm, and mild symptoms has the lowest risk.

My call: low ejection fraction, worse NYHA class, larger heart size, and atrial fibrillation predict deterioration after digoxin withdrawal, and the elderly are at higher risk because of age-related pharmacokinetic changes and polypharmacy. Confidence: moderate — the predictors are well-established from PROVED and RADIANCE, but the age-specific subgroup analysis was never done.

Keep digging

Sources used 2

  1. Digoxin toxicity presenting as dysphagia and dysphonia. BMJ (1991) Thin

    Two case reports from BMJ Drug Points illustrate rare adverse drug reactions—digoxin toxicity presenting as dysphagia and dysphonia, and sulphasalazine-induced chorea—highlighting the need to review medications in elderly patients with new swallowing/voice symptoms or movement d…

    DOI: 10.1136/bmj.302.6783.1025
  2. Atrial natriuretic peptide as a preload depressor in acute renal failure secondary to congestive heart failure Renal Failure (1998) Thin

    This study investigates the effects of atrial natriuretic peptide (ANP) infusion on preload reduction and hemodynamic parameters in patients with acute renal failure secondary to congestive heart failure.

    DOI: 10.3109/08860229809045168

Your question next

What do you want to know?

No question is too uncomfortable for the evidence. Bring yours.

Ask your question